Cediranib (AZD2171) is an active agent in recurrent epithelial ovarian cancer
| Autor: | Karin Tyburski, Jin Hwa Lee, Richard T. Penson, Carolyn N. Krasner, Maria Roche, S. P. Ivy, Martin T. King, Ursula A. Matulonis, Suzanne Berlin, C. Lenahan |
|---|---|
| Rok vydání: | 2008 |
| Předmět: |
Oncology
endocrine system Cancer Research medicine.medical_specialty endocrine system diseases business.industry Angiogenesis food and beverages Highly selective medicine.disease female genital diseases and pregnancy complications Cediranib Active agent Internal medicine Medicine Epithelial ovarian cancer Tyrosine business Ovarian cancer medicine.drug |
| Zdroj: | Journal of Clinical Oncology. 26:5501-5501 |
| ISSN: | 1527-7755 0732-183X |
| DOI: | 10.1200/jco.2008.26.15_suppl.5501 |
| Popis: | 5501 Background: Angiogenesis is important for ovarian cancer growth; blocking angiogenesis can lead to ovarian cancer regression. Cediranib (AZD2171) is a highly selective and potent oral tyrosine... |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|